Skip to main content

Table 1 Patient characteristics and their correlations with the nucleic acid levels and protease/caspase activities in blood

From: Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression

  Patients (%) Nucleosome levels DNA levels Protease activities Caspase activities
   Mean values ± Standard Deviation
Median
Percentiles (10th, 90th)
Breast Cancer Patients
Total 63     
Age 56 years (range 34 - 82 years)   
Distant metastasis     
£ M0 31 (49.2) 1 878 ± 123
851
767, 1078
2 8241 ± 701
8293
7232, 9195
3 22218 ± 12236
12682
10401, 35242
35895 ± 62242
7990
2550, 134240
$ M1 32 (50.8) 1 894 ± 112
841
812, 1076
2 9933 ± 4430
8756
7237, 16836
3 32337 ± 9021
33326
13573, 45296
11486 ± 9167
8570
4718, 31628
# Tumor stage      
pT1-2 29 (53.7) 866 ± 31
858
822, 1058
8352 ± 728
8528
6559, 10246
4 11042 ± 750
10966
10412, 41664
5 5386 ± 2042
5545
2655, 24540
pT3-4 25 (46.3) 829 ± 125
769
763, 1079
7690 ± 389
7564
7240, 19519
4 30439 ± 10052
34378
12258, 42790
5 66341 ± 93967
26670
2736, 181806
# Lymph node metastasis    
N0 13 (23.6) 6 814 ± 80
769
767, -
8027 ± 518
8011
7517, -
26649 ± 14005
34216
10488, -
19370 ± 17547
12350
6420, -
N1-3 42 (76.4) 6 860 ± 85
844
781, 1079
8079 ± 737
8149
6901, 10904
17366 ± 10972
11167
10408, 43572
34821 ± 74658
6890
2613, 66132
# Grading      
I-II 25 (46.3) 813 ± 39
827
762, 1057
7914 ± 896
7885
6807, 9056
18737 ± 11916
11964
10001, 37741
47295 ± 99075
7570
2544, 225815
III 29 (53.7) 878 ± 98
878
768, 1118
8183 ± 494
8137
6984, 15827
19819 ± 12451
11165
10469, 39564
19671 ± 27313
6655
2907, 51685
# Estrogen receptor     
positive 41 (68.3) 846 ± 92
837
767, 1078
7924 ± 719
7868
7185, 9298
20468 ± 12204
11964
10356, 45976
38382 ± 77766
7570
2547, 97376
negative 19 (31.7) 861 ± 65
885
767, -
8428 ± 445
8351
6357, -
16574 ± 11766
10827
10423, -
14330 ± 16701
6655
4670, -
# Progesterone receptor     
positive 36 (60) 825 ± 44
830
768, 1010
7927 ± 796
8124
6949, 9039
17617 ± 11811
11163
10135, 46261
7317 ± 4533
7152
2532, 25178
negative 24 (40) 875 ± 107
865
764, 1144
8209 ± 561
8149
6805, 18757
21094 ± 12382
12682
10456, 35961
55703 ± 90000
6890
2910, 164920
# HER2      
positive 23 (39.7) 855 ± 88
844
767, 1078
8148 ± 628
8149
7249, 9183
19548 ± 11973
11167
10312, 39775
35294 ± 74482
6890
2544, 114262
negative 35 (60.3) 832 ± 70
823
772, 1193
7774 ± 919
8011
6397, 24618
18650 ± 13486
11245
10564, 45011
17637 ± 18799
7150
4765, 38669
Benign Breast Tumor Patients
Total 20     
Age 49 years (range 18 - 79 years)   
   831 ± 102
794
768, 922
9306 ± 1156
8837
7611, 11240
16837 ± 5295
14845
14697, 30293
5580 ± 4186
4610
2714, 9307
Leukocytes      
<10.7/nl 16 (80) 808 ± 61
788
768, -
9471 ± 1068
9191
8496, -
18044 ± 6780
15016
14689, -
4957 ± 2485
4550
2710, -
>10.7/nl 1 (5) 1228
-
-, -
11626
-
-, -
-
-
-, -
3010
-
-, -
CRP      
<0.5 mg/dl 11 (55) 780 ± 16
780
768, -
9191 ± 235
9191
9024, -
24387 ± 10441
24387
17004, -
5835 ± 4363
5835
2750, -
>0.5 mg/dl 5 (25) 823 ± 72
795
772, -
9611 ± 1343
9281
8496, -
14873 ± 197
14831
14689, -
4518 ± 1782
4550
2710, -
CEA      
<3.5 ng/ml 15 (75) 815 ± 65
791
768, -
9383 ± 1169
9024
8496, -
18715 ± 7354
15141
14771, -
5292 ± 2622
5820
2710, -
>3.5 ng/ml 1 (5) 772
-
-, -
9913
-
-, -
14689
-
-, -
3280
-
-, -
CA-125      
<65 U/ml 15 (75) 808 ± 61
788
768, -
9471 ± 1068
9191
8496, -
18044 ± 6780
15016
14689, -
4957 ± 2485
4550
2710, -
>65 U/ml 2 (10) 1011 ± 307
-
-, -
9926 ± 2404
-
-, -
14799
-
-, -
3735 ± 1025
-
-, -
Healthy Women
Total 28     
Age 41 years (range 21 - 67 years)   
   726 ± 50
725
715, 809
7747 ± 678
7641
7175, 8801
21133 ± 8028
14996
13166, 30500
5182 ± 2379
5075
3064, 9277
  1. £M0, patients with localized breast cancer
  2. $M1, patients with metastatic breast cancer
  3. #parameters of M0 patients
  4. 1p = 0.01, 2p = 0.04, 3p = 0.008, 4*p = 0.009, 5p = 0.009, 6p = 0.004
  5. p values as determined by Mann and Whitney-U test (in bold)
  6. *p values as determined by T test (in bold)